Oral Semaglutide Improves Heart Failure Health Status and Drives Significant Weight Loss in HFrEF, T2D, and Obesity
Background
Patients with heart failure with reduced ejection fraction (HFrEF), type 2 diabetes (T2D), and obesity face a complex disease burden with limited therapeutic options that address all comorbidities simultaneously. While glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated benefits in managing T2D and obesity, and some evidence suggests their role in heart failure with preserved ejection fraction (HFpEF), robust real-world data on their efficacy and safety specifically in HFrEF remains scarce. This gap highlights the need for studies evaluating GLP-1 RAs like oral semaglutide in this vulnerable patient population.
Study Design
This observational, retrospective, real-world study utilized a 1:1 propensity score-matched analysis to compare patients treated with oral semaglutide (Oral-Sema Group) against a control group not receiving GLP-1 RAs. A total of 162 patients were included in each group after matching, with a mean age of 71.0 years, mean body mass index of 32.1, and 52.9% females. The primary outcomes assessed were heart failure health status, defined as a ≥5 point difference in the Kansas City Cardiomyopathy Questionnaire (KCCQ) total symptom score, and the change in body weight, both evaluated over a 24-month period.
Results
Patients receiving oral semaglutide demonstrated significantly improved heart failure health status compared to controls. The Oral-Sema Group was 2.45 times more likely to experience an improvement in heart failure health status from baseline to 24 months (95%CI: 1.25-3.65; p = 0.012). This improvement was accompanied by substantial weight loss:
The mean change in body weight was -8.0 ± 2.1 kg in patients treated with oral semaglutide, significantly greater than the -1.9 ± 1.0 kg observed in control patients (p < 0.01).
Furthermore, after 24 months of treatment, negative correlations were identified between the KCCQ total symptom score and body weight (r = -0.558, p < 0.01), as well as glycated hemoglobin (r = -0.491, p = 0.017), suggesting that improvements in metabolic parameters are linked to better cardiac health status. The study also reported good tolerability and safety for oral semaglutide in this cohort.
Key Findings
- Oral semaglutide increased the likelihood of improved heart failure health status by 2.45 times (OR: 2.45, p = 0.012).
- Patients on oral semaglutide lost an average of 8.0 ± 2.1 kg body weight over 24 months (p < 0.01).
- Improved
KCCQscores negatively correlated with body weight (r = -0.558, p < 0.01) after treatment. - Improved
KCCQscores negatively correlated withglycated hemoglobin(r = -0.491, p = 0.017) after treatment. - Oral semaglutide demonstrated good tolerability and safety in this patient cohort.
Why It Matters
Oral semaglutide offers a promising, multi-faceted therapeutic option for patients grappling with the triple burden of HFrEF, T2D, and obesity. This real-world evidence reinforces its efficacy beyond just glycemic control and weight management, demonstrating direct benefits on cardiac health status. For clinicians and patients, an oral GLP-1 RA presents a convenient and potentially more adherent treatment modality compared to injectables, simplifying complex regimens. The observed correlations between weight loss, glycemic control, and improved heart failure symptoms suggest that targeting metabolic health with oral semaglutide can yield significant improvements in overall cardiovascular well-being, potentially reducing hospitalizations and improving quality of life in this high-risk population.
semaglutide
oral semaglutide
heart failure
hfrEF
type 2 diabetes
obesity